Canada offers a solid market for biologics and biosimilars, but market authorization doesn’t come easy. It takes real preparation and tight compliance with Health Canada’s standards. Manufacturers who understand these requirements early tend to avoid validation issues and unnecessary review delays.
Regulatory authorities, documentation, clinical requirements, timelines, fees, labelling, post-market obligations, this article covers all of it, exactly what registration actually demands.
Regulatory Authority for Biologics and Biosimilars in Canada
Health Canada is the Canada Biologics Regulatory Authority, and it’s responsible for Health Canada Biologics Approval and Health Canada Biosimilars Regulation.
In practice, though, it’s spread across several bodies. Each one has a distinct job.
| Authority | Role |
| Health Canada |
Holds legal authority over drug safety, efficacy and quality under the Food and Drugs Act
|
| Health Products and Food Branch (HPFB) |
Administrative branch responsible for the review directorates
|
| Biologic and Radiopharmaceutical Drugs Directorate (BRDD) |
Reviews and authorizes biologic drugs, biosimilars, vaccines, blood products and gene/cell therapies
|
| Therapeutic Products Directorate (TPD) |
Reviews conventional pharmaceuticals
|
| Marketed Health Products Directorate (MHPD) |
Monitors safety once a product is already on the market
|
| Public Health Agency of Canada (PHAC) |
Runs national immunization programs, separate from licensing
|
BRDD manages the review of biologic drugs, biosimilars, vaccines, blood products, oncology products and clinical trial applications through dedicated scientific review offices.
Manufacturers should not confuse Health Canada’s approval process with reimbursement assessments conducted by CDA-AMC and provincial drug plans. Canada’s Drug Agency (CDA-AMC, the renamed CADTH) and provincial drug plans decide whether a biologic gets funded, through health technology assessments and reimbursement reviews. They have no authority over whether a product can legally be sold. That decision belongs to Health Canada alone. A biologic can hold a valid NOC and still be waiting months for a positive CDA-AMC recommendation before any province agrees to pay for it.
Health Canada Biologics and Biosimilars Regulatory Requirements
Before a submission goes anywhere near BRDD, a few baseline requirements have to be in place because most early delays trace back to skipping them.
The Food and Drugs Act and Food and Drug Regulations: Pre-market review of biologics runs under Division 8. Product-specific requirements such as contamination prevention, lot release, periodic quality reporting and labelling are contained in the modernized Division 4. This updated division came into force on July 1, 2025. It replaced regulations that had remained largely unchanged since the 1950s and 1960s.
Biosimilar-specific guidance: Health Canada substantially revised its Guidance Document on Information and Submission Requirements for Biosimilar Biologic Drugs in May 2026.
Format: Submissions must be filed in eCTD, per Health Canada’s eCTD preparation guidance
Manufacturing: Sites must demonstrate Good Manufacturing Practices per GUI-0027. The document is the biologics-specific annex to Health Canada’s GMP guide and was most recently revised in July 2024. Before commercial distribution, a Drug Establishment Licence may also be required.
International alignment: Health Canada draws on ICH guidelines where they apply.
The May 2026 biosimilar guidance revision introduced significant changes, covering clinical evidence expectations, indication justification and terminology, including the adoption of Canadian Reference Biologic Drug (CRBD).
Biologics and Biosimilars Registration Process in Canada
The Biologics Approval Process in Canada runs through the New Drug Submission (NDS) route, filed with BRDD’s Office of Regulatory Affairs. The Biosimilars Approval Process in Canada follows the same route.
Step 1: Pre-submission meeting (optional but recommended)
Manufacturers of complex or novel biologics can request a meeting with BRDD before filing. It’s a chance to surface comparability or data-package concerns before they become formal deficiencies later.
Step 2: Submission filing
The NDS is filed in eCTD format through BRDD’s Office of Regulatory Affairs, which screens and validates submissions and applications.
Step 3: Validation screening
BRDD checks if the dossier is complete and correctly structured. Incomplete or inconsistent Module 3 quality data is a common reason submission get sent back at this stage.
Step 4: Scientific review
Assessors evaluate quality, non-clinical, and clinical data.
Step 5: Quality assessment
The manufacturing process and control strategy are reviewed in detail. Biologics get more scrutiny here than conventional pharmaceuticals because of manufacturing variability.
Health Canada inspects the actual manufacturing facility as part of the quality review, confirming the site can consistently produce a safe biologic. This is distinct from a paper-based GMP review and is specific to biologics.
Step 6: Non-clinical assessment
For biosimilars, this is substantially reduced compared to a novel biologic, relying instead on comparability to the CRBD.
Step 7: Clinical assessment
For biosimilars, this centers on the comparability exercise, including PK and, where feasible, PD, rather than standalone efficacy proof.
Step 8: Benefit-risk evaluation
BRDD weighs the evidence to determine whether benefits outweigh risks and whether risks can be adequately managed.
Step 9: Notice of Compliance (NOC)
Issued once the submission clears review.
Step 10: Drug Identification Number (DIN)
Assigned alongside the NOC. A DIN is required before the product can legally be sold in Canada. This is the point of market authorization.
Step 11: Lot release
Market authorization doesn’t end oversight at the batch level. Every lot of an authorized biologic is assigned to one of four risk-based groups under Health Canada’s Lot Release Program, ranging from full sample testing (Group 2) to periodic notification only (Group 4), and must clear this check before that specific lot can be sold.
Documents Required for Biologics and Biosimilars Registration
Biological Medicinal Products Registration in Canada uses the eCTD format across five modules:
- Module 1 – administrative information, Canadian-specific forms, Product Monograph
- Module 2 – quality, non-clinical, and clinical summaries
- Module 3 – manufacturing information and quality documentation
- Module 4 – non-clinical study reports
- Module 5 – clinical study reports, including biosimilar comparability data
Other required documents include:
- GMP evidence for every manufacturing site involved
- A Risk Management Plan, submitted per Health Canada’s current RMP guidance
- Complete manufacturing site information, including any contract manufacturers
Clinical Trial Requirements for Biologics and Biosimilars
Both Canada Biologics Clinical Trial Requirements and Canada Biosimilars Clinical Trial Requirements share the same starting point. That’s a Clinical Trial Application or CTA, filed under Part C, Division 5 of the Food and Drug Regulations.
Good Clinical Practice has to be followed throughout. Research Ethics Board approval is required too, before any trial can proceed.
Clinical expectations diverge sharply from there:
- A new biologic generally needs the conventional non-clinical through Phase III program
- According to Health Canada’s May 2026 guidance, a biosimilar does not typically need comparative clinical efficacy studies where analytical characterization already demonstrates high similarity to the CRBD
- Biosimilar clinical work instead centres on comparative PK studies and PD data
- Immunogenicity is addressed primarily through analytical and functional data, with clinical PK studies playing a supportive, descriptive role rather than serving as primary evidence
Labelling Requirements for Biologics and Biosimilars
Biologics Labelling Requirements in Canada centre on the Product Monograph, in three parts:
- Part I – Health Professional Information
- Part II – Scientific Information
- Part III – Patient Medication Information, written in plain language
Prescription biologics must be supplied to Health Canada in both English and French.
For biosimilars specifically:
- The Product Monograph must carry a statement identifying the product as a biosimilar to its Canadian Reference Biologic Drug
- It cannot claim therapeutic equivalence to the CRBD
- It cannot include any statement about interchangeability or switching because that determination falls entirely outside Health Canada’s authority.
Timeline for Biologics and Biosimilars Approval
Health Canada’s official performance standard for a New Drug Submission involving a new active substance is 300 calendar days to complete Review 1. This excludes time spent responding to Health Canada’s information requests. Build that response time into internal launch planning rather than treating 300 days as the full clock to market.
Biosimilars are reviewed by Health Canada as New Drug Submissions and are subject to this same general pre-market review framework under Division 8.
Priority Review, granted for serious or life-threatening conditions with no adequate existing treatment, can shorten the review target to 180 days for eligible submissions.
Fees for Biologics and Biosimilars Registration
Health Canada updates its fee schedule every April 1. And fees rise automatically each year with inflation (CPI), under the Fees in Respect of Drugs and Medical Devices Order.
Fees as of April 1, 2026:
| Submission class | Fee (CAD) |
| New active substance | $616,593 |
| Clinical/non-clinical + manufacturing data | $319,282 |
| Clinical or non-clinical data only | $127,668 |
| Comparative studies (biosimilars) | $71,953 |
| Manufacturing data only | $44,269 |
For comparison, the 2025 fee for a new active substance was $606,286. And these numbers change every year, not just occasionally.
Most biosimilars fall under Comparative studies, since they rely on comparability data rather than a new active substance. Novel biologics usually fall under the New active substance category instead.
PMS Requirements for Biologics and Biosimilars
Biologics Post Marketing Surveillance (PMS) Canada obligations begin the moment the NOC takes effect. And they continue for as long as the product remains on the market.
Pharmacovigilance Requirements for Biologics Canada include:
- Adverse drug reaction reporting through Canada Vigilance within defined timeframes
- A Risk Management Plan, submitted per Health Canada’s Submitting Risk Management Plans guidance document, effective July 1, 2025 (this will be formalized directly into the Food and Drug Regulations from April 2027)
- Ongoing signal detection and safety monitoring
- Periodic safety reporting where required as a condition of authorization
- Supplemental submissions for manufacturing or post-approval changes, given how sensitive biological manufacturing is to process shifts
- Health Canada inspections of manufacturing and pharmacovigilance systems
- Product quality complaint handling and recall or defect reporting
Conclusion
Biologics and Biosimilars Regulatory Requirements in Canada aren’t fundamentally more complex than other jurisdictions. The real challenge is the layered structure. BRDD handles authorization and CDA-AMC handles reimbursement, so manufacturers expecting one office to manage everything tend to run into delays.
To get things done without unnecessary back-and-forth, get GMP and pharmacovigilance systems ready early. And scope biosimilar clinical data against BRDD’s May 2026 guidance, not an older filing.
Need help with biologics or biosimilars regulatory documentation, or with planning your market entry into Canada? info@artixio.com works with manufacturers on exactly this, reach out for guidance built around your specific regulatory goals.
FAQs
Q1. Is a separate Health Canada authorization required if a biologic is already approved by the FDA or EMA?
Yes. Health Canada does not automatically recognize foreign approvals for biologics. A full NDS still goes to BRDD, though foreign approval data can support the credibility of the Canadian submission during review.
Q2. Do biosimilars in Canada need full Phase III efficacy trials?
Not typically, as of Health Canada’s May 2026 guidance revision. Where analytical, quality, and comparative PK data make a strong case for high similarity, a standalone efficacy trial is not required. It remains assessed on a case-by-case basis.
Q3. What’s the difference between Health Canada and CDA-AMC in the biologics approval process?
Health Canada decides whether a biologic can legally be sold in Canada. CDA-AMC assesses whether provincial and federal drug plans should fund it. A product can hold a valid NOC and still be waiting on a CDA-AMC recommendation before any public plan pays for it.
Q4. Are biosimilars interchangeable with their reference biologic in Canada?
Health Canada doesn’t decide interchangeability. That determination falls under the authority of individual provinces and territories, and rules differ across jurisdictions. But a biosimilar Product Monograph is specifically barred from making any interchangeability claim.
Q5. What causes the most delays in Canadian biosimilar submissions?
Incomplete or inconsistent Module 3 quality data, comparability studies run against the wrong CRBD batches and skipping the pre-submission meeting where BRDD would otherwise flag issues early.
Q6. How long does a biologic or biosimilar take to get a Notice of Compliance in Canada?
Health Canada’s published performance standard is 300 calendar days for a standard New Drug Submission, or 180 days under Priority Review where granted. But time spent responding to information requests during review isn’t counted within that window.
Q7. Does a biosimilar need its own Drug Identification Number?
Yes. Every authorized biosimilar receives its own DIN alongside its own NOC. It’s treated as a distinct, separately licensed product, not an extension of the reference biologic’s authorization.
